8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Apr 23, 2026·SEC
BridgeBio Oncology Therapeutics Inc.(BBOT)Earnings, Financials & Key Ratios
BBOT•NASDAQ
Price updated Jun 19, 2026
AboutBridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.Show more
- Revenue$0
- EBITDA-$145M-80.0%
- Net Income-$134M-80.5%
- EPS (Diluted)-4.30-1034.8%
- ROE-44.7%+43.2%
BBOT Key Insights
BridgeBio Oncology Therapeutics Inc. (BBOT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 87.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BBOT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BBOT Price & Volume
BridgeBio Oncology Therapeutics Inc. (BBOT) stock price & volume — 10-year historical chart
Loading chart...
BBOT Growth Metrics
BridgeBio Oncology Therapeutics Inc. (BBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-90.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-289.52%
Return on Capital
10 Years-87548.75%
5 Years-87548.75%
3 Years-116727.24%
Last Year-48%
BBOT Recent Earnings
BridgeBio Oncology Therapeutics Inc. (BBOT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (40%)
Q3 2026Latest
Jun 4, 2026Metric
Actual
Est
EPS
$0.53-2.8%
$0.51
Rev
—
—
Q2 2026
May 12, 2026Metric
Actual
Est
EPS
$0.49+4.5%
$0.51
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.48+24.2%
$0.63
Rev
—
—
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.56-33.3%
$0.42
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 4, 2026 | $0.53vs $0.51-2.8% | — |
| Q2 2026 | May 12, 2026 | $0.49vs $0.51+4.5% | — |
| Q2 2026 | Mar 5, 2026 | $0.48vs $0.63+24.2% | — |
| Q2 2026 | Mar 4, 2026 | $0.56vs $0.42-33.3% | — |
Based on last 12 quarters of dataView full earnings history →
BBOT Peer Comparison
BridgeBio Oncology Therapeutics Inc. (BBOT) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BBIO | 12.98B | 66.27 | -17.49 | 126.26% | -125.17% | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare BBOT vs Peers
BridgeBio Oncology Therapeutics Inc. (BBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBOT Income Statement
BridgeBio Oncology Therapeutics Inc. (BBOT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 186K |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -186K▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M | 168.68M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 43.36K | 3.52K | 8.48M | 7.76M | 24.62M | 28.5M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M | 140.37M |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -186K |
Operating Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.77M▼ 1839985.2% | -80.86M▼ 24.8% | -145.82M▼ 80.3% | -168.86M▲ 0% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | 91.88% | -1839985.23% | -24.84% | -80.33% | - |
EBITDA | -43.36K | -3.52K | -64.68M | -80.66M | -145.21M | -168.12M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | 91.88% | -1837371.59% | -24.7% | -80.04% | -90.31% |
D&A (Non-Cash Add-back) | 0 | 0 | 92K | 208K | 610K | 742K |
EBIT | -43.36K | -3.52K | -64.77M | -80.86M | -145.82M | -168.86M |
Net Interest Income | 0 | 0 | 72K | 8.46M | 11.34M | 13.89M |
Interest Income | 0 | 0 | 72K | 8.46M | 11.34M | 13.89M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 0 | 0 | 72K | 8.18M | 11.78M | 14.77M |
Pretax Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.7M▼ 1837939.8% | -74.28M▼ 14.8% | -134.04M▼ 80.5% | -154.09M▲ 0% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -43.36K▲ 0% | -3.52K▲ 91.9% | -64.7M▼ 1837939.8% | -74.28M▼ 14.8% | -134.04M▼ 80.5% | -154.09M▲ 0% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | 91.88% | -1837939.77% | -14.8% | -80.47% | -90.5% |
Net Income (Continuing) | -43.36K | -3.52K | -64.7M | 7.6M | -134.04M | -154.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.00▲ 0% | -0.00▲ 90.5% | -3.16▼ 1579900.0% | 0.46▲ 114.6% | -4.30▼ 1034.8% | -4.95▲ 0% |
EPS Growth % | - | - | - | 114.56% | -1034.78% | -289.52% |
EPS (Basic) | -0.00 | 0.00 | -3.16 | 0.46 | -4.30 | - |
Diluted Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M | 31.14M | 31.14M |
Basic Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M | 31.14M | 31.14M |
Dividend Payout Ratio | - | - | - | - | - | - |
BBOT Balance Sheet
BridgeBio Oncology Therapeutics Inc. (BBOT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 0 | 0 | 0 | 1.95M | 425.46M | 266.5M |
Cash & Short-Term Investments | 0 | 0 | 0 | 1.7M | 425.46M | 252.28M |
Cash Only | 0 | 0 | 0 | 1.7M | 373.69M | 52.66M |
Short-Term Investments | 0 | 0 | 0 | 0 | 51.77M | 199.62M |
Accounts Receivable | 0 | 0 | 0 | 0 | 386K | 146K |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | -386K | 14.08M |
Total Non-Current Assets | 144.28K | 144.58K | 332.89K | 192.47M | 22.92M | 151.14M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 3.16M |
Fixed Asset Turnover | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 192.45M | 132K | 136.88M |
Other Non-Current Assets | 144.28K | 144.58K | 332.89K | 25.13K | 22.79M | 11.24M |
Total Assets | 144.28K▲ 0% | 144.58K▲ 0.2% | 332.89K▲ 130.3% | 194.42M▲ 58304.2% | 448.38M▲ 130.6% | 417.65M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x |
Asset Growth % | - | 0.21% | 130.25% | 58304.24% | 130.62% | 441.08% |
Total Current Liabilities | 162.64K | 166.46K | 396.46K | 187.51K | 35.04M | 43.26M |
Accounts Payable | 0 | 0 | 0 | 0 | 1.37M | 12.09M |
Days Payables Outstanding | - | - | - | - | - | 9.47K |
Short-Term Debt | 36.96K | 43.11K | 70.09K | 0 | 522K | 538K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 33.15M | 28.61M |
Current Ratio | - | - | - | 10.40x | 12.14x | 6.16x |
Quick Ratio | - | - | - | 10.40x | 12.14x | 6.16x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 5.52M | 2.24M | 2.11M |
Long-Term Debt | 0 | 0 | 0 | 0 | 2.24M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 7M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 5.52M | 0 | 0 |
Total Liabilities | 162.64K | 166.46K | 396.46K | 5.71M | 37.28M | 45.37M |
Total Debt | 36.96K | 43.11K | 70.09K | 0 | 2.77M | 2.64M |
Net Debt | 36.96K | 43.11K | 70.09K | -1.7M | -370.92M | -50.01M |
Debt / Equity | - | - | - | - | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | 0.30x |
Interest Coverage | - | - | - | - | - | - |
Total Equity | -18.36K▲ 0% | -21.88K▼ 19.2% | -63.57K▼ 190.6% | 188.72M▲ 296969.0% | 411.1M▲ 117.8% | 372.28M▲ 0% |
Equity Growth % | - | -19.18% | -190.57% | 296969.04% | 117.84% | 319.64% |
Book Value per Share | -0.00 | -0.00 | -0.00 | 11.34 | 13.20 | 11.95 |
Total Shareholders' Equity | -18.36K | -21.88K | -63.57K | 188.72M | 411.1M | 372.28M |
Common Stock | 288 | 288 | 460 | 192.45M | 8K | 8K |
Retained Earnings | -43.36K | -46.88K | -88.57K | -3.73M | -356.57M | -398.67M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 16K | -981K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
BBOT Cash Flow Statement
BridgeBio Oncology Therapeutics Inc. (BBOT) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | 0 | 0 | 0 | -763.82K | -113.89M | -172.07M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | - | - | - | -14811.1% | -132786.18% |
Net Income | -74 | -3.52K | -41.69K | 7.6M | -134.04M | -154.09M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K | 977K |
Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M | 3.82M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 74 | 3.52K | 26.69K | -8.53M | 7.23M | -33.38M |
Working Capital Changes | 0 | 0 | 15K | -104.61K | 6.43M | 10.61M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 172.51K | -1.84M | 6.22M |
Cash from Investing | 0 | 0 | 0 | -184M | 73.33M | -202.44M |
Capital Expenditures | 0 | 0 | 0 | 0 | -606K | -861K |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 0 | 0 | 186.46M | 383.4M | 402.65M |
Debt Issued (Net) | 0 | 0 | 0 | -209.85K | 0 | 373.46M |
Equity Issued (Net) | 0 | 0 | 0 | 187.25M | 395.72M | 44.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | -578.55K | -12.32M | -15.66M |
Net Change in Cash | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.7M▲ 0% | 342.84M▲ 20093.2% | 57.3M▲ 0% |
Free Cash Flow | 0▲ 0% | 0▲ 0% | 0▲ 0% | -763.82K▲ 0% | -114.5M▼ 14890.4% | -172.93M▲ 0% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | - | - | - | -14890.44% | -329.8% |
FCF per Share | - | - | - | -0.05 | -3.68 | -5.55 |
FCF Conversion (FCF/Net Income) | - | - | - | 0.01x | 0.85x | 1.12x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
BBOT Key Ratios
BridgeBio Oncology Therapeutics Inc. (BBOT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -78.74% | -44.7% | -61.49% |
Return on Invested Capital (ROIC) | -13.26% | -350050.44% | -64.85% | -96.27% | -344.92% |
Debt / Equity | - | - | - | 0.01x | 0.01x |
FCF Conversion | - | - | 0.01x | 0.85x | 1.12x |
Related:BBOT Dividend History·BBOT Revenue History·BBOT Price History·BBOT P/E History·BBOT Financial Ratios·BBOT Institutional Holders
BBOT SEC Filings & Documents
BridgeBio Oncology Therapeutics Inc. (BBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
BBOT Frequently Asked Questions
BridgeBio Oncology Therapeutics Inc. (BBOT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BridgeBio Oncology Therapeutics Inc. (BBOT) grew revenue by 0.0% over the past year. Growth has been modest.
BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $154.1M for fiscal year 2025.
Dividend & Returns
BridgeBio Oncology Therapeutics Inc. (BBOT) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
BridgeBio Oncology Therapeutics Inc. (BBOT) had negative free cash flow of $172.9M in fiscal year 2025, likely due to heavy capital investments.